

## Corporate Fact Sheet

### COMPANY HIGHLIGHTS:

- Clear focus on developing tests for early detection of cancer and for personalized cancer treatment decisions
- Broad product pipeline consists of over ten products
- Three products based on OncoMethylome's technology were launched in the US by LabCorp in 2008
- MGMT Methylation assay for predicting patient response to standard brain cancer therapy launched in the US.
- Commercialization of certain products in Europe planned for the near-term
- Strong commercialization partners include LabCorp and Veridex (J&J)
- Strong pharmacogenomic collaboration partners include Schering-Plough, Abbott, GSK Biologicals, Merck KGaA
- Patents granted in USA, Europe and Japan on methylation detection technology and methylation markers
- Collaborations with renowned oncology opinion leaders in the US and Europe

### MEDIA AND INVESTOR INQUIRIES:

**Mr. Philip Devine**

+32 4 364 20 70

IR@oncomethylome.com

[www.oncomethylome.com](http://www.oncomethylome.com)

## About OncoMethylome Sciences

OncoMethylome is a molecular diagnostics company committed to developing novel, accurate, and informative diagnostic tests for early detection of cancer and for personalizing cancer treatment decisions. OncoMethylome was founded in 2003, is headquartered in Belgium, and has offices and laboratories in Belgium, the Netherlands, and Durham, NC, USA.

## Product Pipeline

### Diagnostic Tests for Early Detection of Cancer

Over one third of all people develop cancer during their lifetime. One of the best ways to survive cancer is to detect it early when it is still confined to the organ of origin and is therefore most effectively treatable. OncoMethylome is developing novel molecular tests for detecting early-stage cancer. In 2008, our US commercial partner, LabCorp launched early detection tests for prostate and colorectal cancer. Additional diagnostic products in the development pipeline include tests for detection of prostate, colorectal, bladder, lung, breast and cervical cancers.

### Tests for Personalizing Cancer Treatment

OncoMethylome also develops molecular tests (pharmacogenomics) for helping doctors select the most appropriate cancer treatment for their patients. By analyzing the molecular make-up of a patient's tumor, the tests aim to provide clinicians with additional information on probability of therapy response and/or risk of recurrence. The first commercially available product in this category is the MGMT methylation test for predicting response to alkylating agents used to treat advanced brain cancers. Studies have shown that patients with a methylated MGMT gene are more likely to respond to standard therapy regimens than patients with unmethylated MGMT. Other tests for predicting tumor response to cancer drug therapies and risk of recurrence are in development, often in partnership with leading pharmaceutical companies.

TARGET INDICATION	PRODUCT TYPE	CORPORATE PARTNER	DEVELOPMENT STAGE				SALES	
			MI	MAD	CV	LSKD	LSS	RR/KS
<b>Prostate Cancer</b>	Tissue test Urine screening test	LabCorp, J&J J&J				■	■	
<b>Multiple Cancers</b>	MGMT Pharmacogenomic test	LabCorp, Schering-Plough, Merck KGaA					■	
<b>Colorectal Cancer</b>	Stool screening test Blood screening test	LabCorp			■		■	
<b>Bladder Cancer</b>	Urine screening test				■			
<b>Lung Cancer</b>	Early detection test Recurrence prediction test			■		■		
<b>Cervical Cancer</b>	Diagnostic test			■				
<b>Undisclosed Cancers</b>	Pharmacogenomic test	Abbott, GSK Biologicals		■				
<b>Breast Cancer</b>	Diagnostic test			■				

• MI: Marker Identification

• CV: Clinical Verification

• LSS: Lab Service Sales


• MAD: Marker & Assay Development

• LSKD: Lab Service & Kit Development

• RR/KS: Regulatory Review/Kit Sales

■ : Diagnostic Test

■ : Personalized Treatment Test



**EURONEXT SYMBOL:**

- **Brussels:** ONCOB
- **Amsterdam:** ONCOA

**EMPLOYEES: 67**

**SELECT MEMBERS OF  
MANAGEMENT TEAM:**

- **Herman Spolders, Drs.**  
*Chief Executive Officer*
- **Philip Devine, CPA, MBA**  
*Chief Financial Officer*
- **Gert-Jan Renardel de Lavalette,**  
*Chief Operations Officer*
- **Harry Schrickx,**  
*VP, Business Development  
and Marketing*
- **Joseph Bigley, MS**  
*VP, Clinical Development*
- **James DiGuseppi, PhD**  
*Chief Technology Officer*

**CONTACT DETAILS:**

**Europe Head Office**

OncoMethylome Sciences SA  
Tour 5 Giga, niv. +3  
Av. de l'Hopital 11  
4000 Liège  
Belgium  
**T:** (+32) 4 364 20 70  
**F:** (+32) 4 364 20 71

**USA Head Office**

OncoMethylome Sciences Inc  
2505 Meridian Parkway  
Suite 310  
Durham, NC 27713  
USA  
**T:** +1 919 281 0980  
**F:** +1 919 281 0981

[www.oncomethylome.com](http://www.oncomethylome.com)

**Commercialization Plans and Corporate Partners**

OncoMethylome commercializes its products via global diagnostic companies and service laboratories with established sales and marketing capabilities. In the U.S., Laboratory Corporation of America (LabCorp) launched three products in 2008 based on OncoMethylome's technology: a tissue-based test for early detection of prostate cancer, a stool-based test for colorectal cancer screening, and MGMT, OncoMethylome's first personalized medicine test for predicting response to alkylating agent drugs used in brain cancer therapy. Efforts are now underway to commercialize OncoMethylome's assays in Europe. In addition, Veridex LLC, a Johnson & Johnson company, licensed tissue- and urine-based tests for early detection of prostate cancer. In exchange for commercialization rights, OncoMethylome typically receives upfront and milestone payments and is entitled to payments related to product sales.

When developing personalized treatment tests (pharmacogenomics), OncoMethylome works closely with pharmaceutical partners, including Schering-Plough Corporation, Abbott, GlaxoSmithKline Biologicals and Merck KGaA. These collaborations use OncoMethylome's Biomarker Discovery Program, which can identify novel methylation biomarkers, and/or development and clinical validation of methylation markers that correlate to therapy response.

**Methylation Technology**

OncoMethylome owns an exclusive license from Johns Hopkins University to patent-protected technology for detecting DNA hyper-methylation, called Methylation-Specific PCR (MSP). DNA hyper-methylation, or silencing, of genes has been correlated with the development and progression of cancer and tumor response to drug treatments. In the 1990s, scientists at Johns Hopkins University (USA) made a breakthrough invention when they developed technology for detecting DNA hyper-methylation. This MSP technology is capable of discovering cancer cells within a large background of healthy cells, rendering it very effective for detecting cancer in routine samples such as urine and blood. OncoMethylome develops its products by combining the MSP technology with patent-protected marker genes known to be hyper-methylated in human cancers. The oncology community has repeatedly demonstrated the potential advantages of MSP technology and OncoMethylome's marker portfolio over other approaches.

**Academic and Clinical Partners**

OncoMethylome's research and clinical development program collaborates with many of the world's leading cancer research institutes. These relationships provide additional resources and expertise as well as access to clinical samples. Among these leading oncology centers are Johns Hopkins University, Fox Chase Cancer Center, Duke University, University of Colorado (all US), Spanish National Cancer Institute (Spain), GROW Institute at the University Hospital of Maastricht (The Netherlands), Amsterdam Free University Medical Center (The Netherlands), The University Hospital of Groningen (The Netherlands), University of Ghent (Belgium) and University of Liège (Belgium).